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INTRODUCTION
In colon cancer, lymph node (LN) sta-
tus is a strong prognosticator that usu-
ally guides adjuvant chemotherapy
when regional LN metastasis (pN+) is
found in the resected specimen. Obtain-
ing an adequate LN harvest is therefore
essential for guiding postoperative treat-
ment. The LN harvest has become an ex-
tensively investigated quality standard
for both surgeons and pathologists (1–4),
and the number of LNs examined is as-
sociated with survival (2). The recom-
mended number of nodes for appropri-
ate staging is a minimum of 12 (5),
although this goal has been achieved in
as low as 50% of the patients (6). Factors
associated with either a poor (<12 nodes)
or adequate (≥12 nodes) LN harvest is
the subject of extensive debate (7–10).
Notably, few studies have investigated
the molecular pathways in colorectal car-
cinogenesis and their potential relevance
for the LN harvest. However, in a previ-
ous cohort, we found that microsatellite
instability (MSI) was associated with the
total number of LNs harvested (11),
which has been confirmed by others
(12,13). The aim of the present study was
to further investigate MSI and KRAS and
BRAF mutations and their relationship to
the number of harvested LNs in colon
cancer patients.
MATERIALS AND METHODS
Study Population
The study population comprised a
prospective patient series with stage I–III
colon cancer enrolled in a sentinel node
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project, as previously described (14).
Briefly, all the patients underwent elec-
tive surgery with a curative intent at the
Department of Surgery of Stavanger Uni-
versity Hospital in Stavanger, Norway,
from June 2003 to February 2010. The pa-
tients were prospectively included after
providing informed consent.
The Norwegian health system covers
all medical expenses for diagnosis, man-
agement and surveillance, indicating no
systematic selection bias in the cohort
presented. Stavanger University Hospital
provides all surgical services to a prima-
rily Western population catchment area
of approximately 330,000 inhabitants. Ac-
cordingly, the results should be represen-
tative for other Western populations.
Patients were excluded from the study
cohort if any of the following occurred:
noninvasive tumors (T0 and Tis), evi-
dence of distant metastases (M+) at the
time of surgery or on pre-op staging,
preoperative chemotherapy, preoperative
treatment with a self-expanding metal
stent because of acute colon obstruction,
missing tumor biopsies for DNA re-
trieval, missing or incomplete
histopathology report (for node status,
number and pN), or deviations from the
SLN mapping protocol.
Radical surgical resection was applied
to the specific tumor-bearing segment of
the colon by using either an open or a la-
paroscopic technique following general
surgical oncological principles. Tumors
located proximal to the left flexure were
defined as right-sided and tumors from
the left flexure through the sigmoid
colon as left-sided.
Tissue and LN Sampling
Ex vivo sentinel LN mapping was per-
formed on resected specimens from all
patients, as previously described (14). In
the current study, the total numbers of
histologically verified LNs were ana-
lyzed without separating the nodes into
“sentinel” and “nonsentinel” categories.
The resected colonic segment was
evaluated by gross and microscopic
histopathological examination, including
regional LN harvesting, following an in-
Table 1. Characteristics and the associated LN count. 
Number of nodes Number of nodes 
harvested with metastasis 
Feature n (%) [median (range)] Pa [median (range)] Pa
Sex 0.037 0.086
Female 116 (57) 14 (4–39) 0 (0–10)
Male 88 (43) 12 (5–43) 0 (0–17)
Age (years) 0.329 0.447
<75 88 (43) 13 (5–43) 0 (0–8)
≥75 116 (57) 14 (4–35) 0 (0–17)
Stage 0.519b NA
I 40 (20) 13 (4–35) —
II 103 (50) 13 (5–39) —
III 61 (30) 14 (6–43) 2 (1–17)
Histological type 0.653 0.007
Non-mucinous 175 (85) 14 (4–43) 0 (0–8)
Mucinous type 29 (15) 14 (8–32) 0.5 (0–17)
Histological gradec 0.071 0.005
High 147 (72) 13 (4–43) 0 (0–8)
Low 57 (28) 16 (7–32) 0 (0–17)
Tumor invasion 0.248 0.003
pT1-2 47 (23) 13 (4–35) 0 (0–5)
pT3-4 157 (77) 14 (5–43) 1 (0–17)
MSI 0.002 0.693
MSS 137 (67) 14 (4–43) 0 (0–17)
MSI 67 (33) 17 (7–39) 0 (0–10)
KRAS mutation 0.864 0.979
Wild-type 129 (63) 14 (5–35) 0 (0–17)
Mutated 75 (37) 14 (4–28) 0 (0–17)
BRAF mutationd 0.137 0.639
Wild-type 146 (72) 13 (0–43) 0 (0–17)
Mutated 57 (28) 14 (7–39) 0 (0–10)
Location in colon 0.001 0.938
Proximal 145 (71) 14 (0–43) 0 (0–10)
Distal 59 (29) 11 (4–35) 0 (0–17)
Tumor size (cm) 0.030 0.261
<5 85 (41) 12 (4–39) 0 (0–6)
≥5 119 (59) 14 (5–43) 0 (0–17)
aMann-Whitney U test.
bComparison of stage I and II versus stage III.
cHigh = G3/G4, low = G1/G2.
dBRAF mutation status missing for one patient.
Table 2. Prevalence of MSI, KRAS and BRAF and associated LN yield rate.
MSI KRAS codon 12 + 13 BRAF V600E
Node Node Node 
n Prevalence yielda Prevalence yielda Prevalenceb yielda
All 204 67 (33) 53 (79) 75 (37) 51 (68) 57 (28) 41 (72)
Stage I 40 17 (43) 12 (71) 17 (43) 8 (47) 12 (30) 8 (67)
Stage II 103 32 (31) 26 (81) 37 (36) 26 (70) 27 (27) 21 (78)
Stage III 61 18 (30) 15 (83) 21 (34) 17 (81) 18 (30) 12 (67)
Data are n (%) or n.
aNode yield, denotes the rate of patients with ≥12 nodes sampled after surgery.
bMissing data in one patient for BRAF mutation status.
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stitutional template established several
years before the study (15) to determine
the number of LNs present and the dis-
ease stage according to the tumor, node,
metastasis (TNM) staging system of the
Union for International Cancer Control.
The extent of node metastasis was de-
fined as pN0 for node-negative speci-
mens, pN1 for one to three metastatic
LNs and pN2 for three or more metasta-
tic LNs in the specimen.
Outcome
The primary outcome of this study
was the number of LNs harvested, re-
ported either as the total number ob-
served (that is, both sentinels and non-
sentinels, with or without metastasis),
and, alternatively, as the rate of appropri-
ately harvested cases (that is, patients
with ≥12 nodes per specimen, defined as
an adequate harvest). Secondary out-
comes were limited to number of
metastatic LNs (pN+) and to the survival
outcome at follow-up. Cancer-specific
death was used as an endpoint. Patients
alive at the end of follow-up were cen-
sored. Patients who died of other causes
than cancer were censored at time of
death. Follow-up was performed blinded
to the patients’ clinical characteristics or
molecular profile in the study.
Genetic Analyses
A sample from the tumor and the nor-
mal surrounding mucosa was collected
from the resected colonic segment and
was instantly frozen in liquid nitrogen.
DNA was extracted from the tissue by
using either a combination of the RNeasy
Mini Kit and the DNeasy Mini Kit or the
AllPrep DNA/RNA Mini Kit (all manu-
factured by Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s protocols.
The MSI status (microsatellite stable
[MSS]; low frequency [MSI-L], or high
frequency [MSI-H]) was determined by
using Bethesda markers (BAT25, BAT26,
D2S123, D5S346 and D17S250), as de-
scribed (16). For MSI analyses, DNA
from tumor and corresponding normal
tissue were analyzed and compared.
Analyses were run twice, and two people
evaluated all results independently. Pres-
ence of two or more instable markers
was defined as high-frequency MSI
(MSI-H) and only one single unstable
marker as low-frequency MSI (MSI-L).
MSI-L was coded as MSS for the regres-
sion analysis in the current study, as per
convention. Thus, MSI denotes MSI-H if
not otherwise indicated. Mutations in
codons 12 and 13 of the KRAS gene were
detected by peptide nucleic acid clamp
polymerase chain reaction (PCR) (17,18).
The hot-spot mutation V600E in exon 15
of the BRAF gene was identified by
using PCR and Sanger sequencing, as
previously described (19).
For BRAF mutation analysis, all PCR
products were sequenced in the 5′ direc-
tion, and electropherograms were scored
both manually and semiautomatically by
using Sequencing Analysis (version 5.3.1)
and SeqScape software (version 2.5), re-
spectively. The resulting sequence was
compared with reference sequence
NM_004333 (GenBank). For samples in
which a mutation was found, a confirma-
tory sequencing reaction was performed
in the 3′ direction.
Figure 1. LN counts for MSI status and tumor location in the colon. (A) Total node counts
according to MSI status (MSS, MSI-L or MSI-H). The asterisks indicate statistical significance.
(B) The total LN counts for MSI status according to location in either the proximal or distal
colon. The box-and-whiskers plot shows the medians, interquartile ranges and 95% CIs,
and the circles/asterisks indicate outliers. (C) Adequate LN harvest improved significantly
within the MSS cancers for proximal cancers. Adequate harvest proportion increased sig-
nificantly with addition of MSI to either location (P = 0.001 for trend).
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Study Ethics
Written, informed consent was ob-
tained from all the study subjects. This
research project was approved by the Re-
gional Committee for Medical Research
Ethics (REK Vest 197.04, Biobank 15-10)
according to national legislation.
Statistical Analyses
All statistical analyses were performed
by using the software package IBM SPSS
Statistics, version 20 (SPSS, Chicago, IL,
USA). Descriptive data are presented as
medians and ranges (or interquartile
ranges) or as proportions, as appropriate.
Dichotomous variables were tested by χ2
or Fisher exact test, as appropriate. Con-
tinuous variables were analyzed by using
a nonparametric Mann-Whitney U test or
the Kruskal-Wallis test for more than two
groups. For variables associated with the
number of LNs as a continuous outcome
variable, a multiple linear regression ad-
justed for age and sex in a hierarchical
mode was performed, as previously rec-
ommended (20,21). The variables were
analyzed for normality, colinearity and in-
teractions. The factors found to be associ-
ated with a sufficient (≥12 LNs) harvest
were investigated by using univariate and
multivariable analyses and are presented
with odds ratios (ORs) and 95% confi-
dence intervals (95% CIs). The multivari-
able model was adjusted for age and sex
and included variables with P < 0.2.
Goodness of fit was assessed with the
Hosmer-Lemeshow test. Survival analy-
ses were performed with the log-rank
method by using Kaplan-Meier curves.
All the tests were two-tailed, and the sta-
tistical significance was set at P < 0.05.
RESULTS
Patient and Tumor Characteristics
A total of 204 patients with stage I–III
colon cancer and a median age of 76 years
(range 21–93 years) were included. A suf-
ficient number of harvested LNs (defined
as ≥12) was observed in 136 patients
(67%). Clinicopathological characteristics
and molecular features (MSI, KRAS and
BRAF) related to the LN harvest are given
in Table 1. The prevalence of MSI and
KRAS and BRAF mutations for each stage
and the associated number of adequate
node harvest is presented in Table 2.
Total Number of LNs Harvested
Among the 3,068 LNs collected, metas-
tases (pN+) were detected in 173 (5.6%)
nodes. The median number of harvested
nodes was 14 (range 4–43; interquartile
range 11–19), with significantly more
nodes found in women, in proximal lo-
cated tumors, in MSI genotype and
larger (≥5 cm) tumors (Table 1). The total
nodes sampled for each frequency stra-
tum of MSI is presented in Figures 1A–C,
with and without tumor location.
The total number of harvested LNs was
investigated as an outcome variable by
using a multiple linear regression ad-
justed for age, sex, MSI status, BRAF mu-
tation status, tumor location and tumor
size. According to the model, the only sig-
nificant predictor of LN harvest size was
MSI, with a β coefficient of 0.224 (P =
0.02) and a model R2 of 0.07 (F = 2,834;
P = 0.01). Although MSI was the only fac-
tor that was significantly associated with
an increased number of harvested LNs,
the R2 value indicates that only 7% of the
variance in the LN number was explained
by MSI. However, the model demon-
strated a good fit. In addition, MSI had a
significant effect on LN number in stage
I–II cancers only (P = 0.04) after control-
ling for age, sex and tumor location. The
addition of BRAF status to MSI in the
analysis produced an effect of LN harvest
numbers that had borderline significance
(P = 0.05); there was a slight increase in R2
to 0.09, indicating a 9% contribution to the
variance in the model. For stage III can-
cers, proximal location was the only factor
determined to be significantly associated
with an elevated LN count (P = 0.04).
Characteristics Associated with
Adequate LN Harvest
A sufficient LN harvested LNs (defined
as ≥12) was observed in 136 patients
Figure 2. Proportion of patients with adequate node harvest according to MSI and KRAS/
BRAF genotypes. The rates of adequate LN sampling are shown for MSI/MSS tumors with or
without KRAS mutations (A) and MSS/MSI tumors with or without BRAF V600E  mutations (B).
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(67%) of the entire cohort. In patients with
≥12 nodes sampled, 39% (n = 53) exhibited
MSI (P = 0.007), and 79% had tumors lo-
cated in the proximal colon (P = 0.002). In-
versely, among the patients with MSI (n =
67), 79% had ≥12 nodes harvested, and
73% (106 of 145) of the patients with prox-
imal tumors had ≥12 nodes harvested.
The proportion of patients with ade-
quate node harvest varied according to
the presence of MSI, BRAF mutations
and KRAS mutations (Table 2), including
the coexistence of two or more of these
factors (Figure 2). The adequate harvest
proportions (Figure 3) also differed ac-
cording to MSI combined with tumor lo-
cation, age and pT-stage, but neither the
number of metastatic nodes nor the pN+
stage distribution varied according to
MSI status (Figure 3D).
The results of the univariate analysis
of the clinicopathological factors predict-
ing a sufficient LN harvest are summa-
rized in Table 3. The multivariate logistic
regression analysis of MSI status, tumor
location, tumor size and BRAF status,
which controlled for sex and age, re-
vealed that a proximal tumor location
was the only significant predictor of an
LN harvest ≥12, with an adjusted OR of
2.4 (95% CI 1.2–4.9; P = 0.01), a change in
R2 between 0.09 (Cox and Snell) and 0.13
(Nagelkerke) and an appropriate model
estimate (Hosmer-Lemeshow goodness
of fit, P = 0.7).
The same model used to analyze the
data from the stage I–II patients (n = 143)
produced no significant predictors of a
sufficient LN harvest. However, it re-
vealed that a proximal location was a
predictor of a sufficient LN harvest in the
smaller group of stage III patients, with
an OR of 5.7 (95% CI 1.2–27.3; P = 0.03), a
good model fit (Hosmer-Lemeshow P =
0.8) and a corresponding R2 change be-
tween 0.15 and 0.22.
At the time of diagnosis, 88 patients
(43%) were <75 years of age. In this sub-
set, 72% of patients had a sufficient num-
ber of harvested LNs, although the me-
dian number was lower (13, range 0–43)
than that for patients ≥75 years of age
(14, range 4–35). In the subset of patients
<75 years of age, the multivariate regres-
sion analysis revealed no significant fac-
tors associated with a sufficient LN har-
vest. However, for the patients ≥75 years
of age (n = 116), the model revealed that
a proximal location was a predictor of
sufficient LN sampling (OR 5.0, 95% CI
1.9–13.6; P = 0.001), with an R2 change
between 0.18 and 0.24 (Hosmer-
Lemeshow goodness of fit P = 0.6).
Survival at End of Follow-up
At the end of follow-up (median 3.5
years, interquartile range 2.0–5.4 years),
a total of 55 patients died (27%), of
which 18 (8.8%) died of colon cancer.
Stage (Figure 4) predicted cancer-specific
survival at the end of follow-up (stages
I–II, 97% alive, versus stage III, 78%
alive; P < 0.001; hazards ratio 7.0, 95% CI
2.5–19.8) with a nonsignificantly better
prognosis for MSI (Figure 4). The com-
bined negative genetic feature of BRAF
mutated with MSS was significantly
prognostic (Figure 4C). None of the
other clinical variables, neither tumor
variables nor the molecular features, in-
fluenced cancer-specific survival. Also,
there was no difference in cancer-specific
survival for patients with <12 LN versus
those with ≥12 LN. This was consistent
when stratified for features such as
tumor location and genetic subtypes.
DISCUSSION
In this prospective study, an adequate
node harvest (≥12) was achieved in a
high proportion of patients (67%; n =
136), with the best node harvest seen in
patients with MSI tumors (79% had ≥12
nodes) and those with tumors in the
proximal colon (73% had ≥12 nodes). In
total, MSI was demonstrated in 33% of
the patient samples. This is in line with
Figure 3. Proportion of adequate node harvest according to age, location and pT-stage.
(A) Proportion of adequate LN harvest according to age-groups, stratified for MSI status
(P < 0.05 for trend). (B) Proportion of adequate LN harvest according to age and tumor
location (P < 0.05 for trend). (C) Proportion of adequate LN harvest according to pT-stage
and MSI, P < 0.05 for trend. (D) Distribution of pN categories according to MSI status.
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existing literature reporting on MSI for
the different segments of the colon (22).
Tumor location appeared to consis-
tently predict a sufficient number (≥12)
of nodes, which is in line with recent re-
ports (22,23). However, when the factors
affecting the total number of harvested
LNs were assessed and adjusted for age
and sex, MSI was the only significant
factor, explaining 11% of the change in
the regression model. Furthermore, a
specific genotype combination (that is,
MSI with wild-type KRAS/BRAF) was
associated with a higher rate of ade-
quate LN harvest (>83%), whereas the
presence of mutations in both KRAS and
BRAF was associated with lower rates of
adequate node sampling, even for tu-
mors within the proximal colon. The im-
portance of combining genetic features
within the colon may point to the previ-
ous concept of a continuum diversity
within the colon rather than the blunt
dichotomized difference in proximal or
distal location (24). Furthermore, the as-
sociated findings of the molecular fea-
tures to the LN harvest in this study
mirrors the previous knowledge that
MSI cancers are associated with a favor-
able prognosis (25), whereas BRAF mu-
tations, which predicted the smallest
number of LN harvest in this study, are
known to be associated with a poor
prognosis (26).
The current results substantiate previ-
ous findings by our group (11) and oth-
ers (12,13) demonstrating an effect of
MSI in determining the actual LN counts
after surgery. Both MSI and proximal
tumor location appear to be associated
with a higher LN harvest, both indepen-
dently and in combination. This relation-
ship has been demonstrated in different
populations with the use of various cut-
offs to determine the appropriate nodal
count (11–13,23). In contrast to these
studies, a Canadian study found no sig-
nificant difference between the effects of
MSI and MSS on LN harvest in 168 se-
lected stage III colon cancer patients (27).
However, the study used the median and
mean node counts as a cutoff, rather than
the guideline of ≥12 nodes suggested for
clinical decision-making. In contrast, the
relationship between MSI and a larger
number of harvested nodes has been
demonstrated in study populations in
Norway (11), France (13), the Nether-
lands (12), and the U.S. (23).
The association between a proximal
tumor location and an increased MSI
prevalence is well established for colo-
rectal cancer. The correlation between
tumor location and node yield may be
confounded by higher-quality surgery
performed for right-sided colon cancers,
or it may indicate anatomical differences,
for example, in the lymphatic system be-
tween the right and left sides of the
colon. However, while we do not neces-
sarily disagree with this, nor can we rule
out the potential confounding effect of
surgery and anatomical differences in the
tumor-bearing segments of the colon, the
finding of molecularly mixed genotypes
and an association with LN count, even
within the proximal colon tumors, argues
against a purely anatomical and/or sur-
gical explanation. Although cancers with
MSI had a higher LN yield, this benefit
was reduced in the presence of BRAF
mutations, a genetic feature associated
with a poor outcome. Furthermore, the
arbitrarily dichotomized locations of
“proximal” and “distal” may be too ap-
proximate of an estimate for exploring
the subsegmental continuum difference
Table 3. Univariate and multivariable analysis of factors associated with sufficient LN
sampling (≥12 nodes). 
LN <12 LN ≥12 Adjusted 
[n (%)] [n (%)] OR (95% CI) Pa OR (95% CI)b Pa
Sex 0.6 (0.3–1.1) 0.089 0.3 (0.7–2.6) 0.329
Female 33 (28) 83 (72)
Male 35 (40) 53 (60)
Age (years) 0.6 (0.3–1.1) 0.110 0.6 (0.3–1.1) 0.061
<75 24 (27) 64 (73)
≥75 44 (38) 72 (62)
Stage 1.4 (0.7–2.8) 0.280 — NA
I and II 51 (36) 92 (64)
III 17 (28) 44 (72)
Histology grade 1.4 (0.7–2.8) 0.279 — NA
High 53 (36) 94 (64)
Low 16 (28) 41 (72)
Tumor size (cm)c 1.8 (1.0–3.3) 0.045 1.6 (0.7–3.5) 0.099
<5 35 (41) 50 (59)
≥5 33 (28) 86 (72)
Tumor invasion 1.5 (0.7–2.9) 0.343 — NA
pT1-2 18 (39) 28 (61)
pT3-4 50 (32) 108 (68)
MSI status 2.5 (1.2–4.9) 0.008 2.3 (0.9–6.3) 0.223
MSS 54 (39) 83 (61)
MSI 14 (21) 53 (79)
KRAS status 1.1 (0.6–2.0) 0.758 — NA
Wild-type 44 (34) 85 (66)
Mutated 24 (32) 51 (68)
BRAF status 1.4 (0.7–2.8) 0.306 — NA
Wild-type 52 (36) 94 (64)
Mutated 16 (28) 41 (72)
Location in colon 2.9 (1.5–5.5) 0.001 2.4 (1.2–4.9) 0.014
Proximal 39 (27) 106 (73)
Distal 30 (51) 29 (49)
aχ2 two-sided test, df = 1.
bMultiple logistic regression.
cLargest diameter of tumor.
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observed in the colon, which affects both
the molecular profile and the LN num-
bers (28). Also, the overall node yield in
the current study was high (over 67%
had adequate node sampling), as a proxy
indicating proper surgery performed for
the majority of patients, and all had R0
resections performed (“R0” denotes a
surgical resection with free margins
proven on histopathology).
Notably, MSI tumors exhibit a charac-
teristic Crohn’s-like lymphoid reaction at
the tumor border (29), which is believed
to be a tumor-targeted immunogenic acti-
vation of specific lymphocytes (30) and
may explain the favorable prognostic
profiles of MSI cancers. Although the cur-
rent study was not designed to provide a
tumor-biological mechanistic explanation,
the consistent findings of more nodes in
tumors with MSI may suggest immuno-
genic mechanisms that favorably influ-
ence tumor biology and, subsequently,
prognosis (31,32). Why more nodes are
found with MSI, yet are reduced when
associated with KRAS or BRAF muta-
tions, remains an intriguing observation
and warrants further investigation.
CONCLUSION
A higher LN yield is found for proxi-
mal tumor location, and the total num-
ber of nodes is influenced by the preva-
lence of MSI, as well as KRAS and BRAF
mutations. Higher yield was not associ-
ated with an increased number of
metastatic nodes in the current study,
which is in agreement with recent large
cohorts (33,34). Each factor likely influ-
ences the LN sample to a modest, yet
significant, degree, as demonstrated by
the multivariable modeling in this se-
ries. This observation is in accordance
with a previous study, in which four
factors collectively explained 19% of the
overall variation in the prediction
model (35). Genetic features should be
considered together with other clinico-
pathological factors when assessing
node count after surgery for colon can-
cer. The information obtained in this
study adds to the evolving knowledge
about diversity in colon cancer features
and points to associations between the
location of the tumor, the underlying
genetic features and the node count.
These factors are associated with the in-
dividual demographic features and
eventually may explain observed vari-
ance in clinical outcomes.
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Figure 4. Cancer-specific survival for stage (A), MSI and MSS (B) and MSI/MSS and BRAF
wt/mut genotypes (C). Hashes on the survival curves denote censored patients.
R E S E A R C H  A R T I C L E
M O L  M E D  1 9 : 2 8 6 - 2 9 3 ,  2 0 1 3  |  B E R G E T  A L .  |  2 9 3
REFERENCES
1. Bilimoria KY, et al. (2008) Adequacy and impor-
tance of lymph node evaluation for colon cancer
in the elderly. J. Am. Coll. Surg. 206:247–54.
2. Chang GJ, Rodriguez-Bigas MA, Skibber JM,
Moyer VA. (2007) Lymph node evaluation and
survival after curative resection of colon cancer:
systematic review. J. Natl. Cancer Inst. 99:433–41.
3. Wang J, et al. (2009) Should total number of lymph
nodes be used as a quality of care measure for
stage III colon cancer? Ann. Surg. 249:559–63.
4. Veen T, et al. (2013) Qualitative and quantitative
issues of lymph nodes as prognostic factor in
colon cancer. Dig. Surg. 30:1–11.
5. Cianchi F, et al. (2002) Lymph node recovery
from colorectal tumor specimens: recommenda-
tion for a minimum number of lymph nodes to
be examined. World J. Surg. 26:384–9.
6. Nathan H, et al. (2011) Variation in lymph node
assessment after colon cancer resection: patient,
surgeon, pathologist, or hospital? J. Gastrointest.
Surg. 15:471–9.
7. Shia J, Wang H, Nash GM, Klimstra DS. (2012)
Lymph node staging in colorectal cancer: revisit-
ing the benchmark of at least 12 lymph nodes in
r0 resection. J. Am. Coll. Surg. 214:348–55.
8. Wright FC, Law CH, Berry S, Smith AJ. (2009)
Clinically important aspects of lymph node as-
sessment in colon cancer. J. Surg. Oncol. 99:248–55.
9. Baxter NN. (2009) Is lymph node count an ideal
quality indicator for cancer care? J. Surg. Oncol.
99:265–8.
10. Nedrebø B, et al. (2013) Risk factors associated with
poor lymph node harvest after colon cancer sur-
gery in a national cohort. Colorectal Dis. 15:e301-8.
11. Søreide K, Nedrebø BS, Søreide JA, Slewa A,
Kørner H. (2009) Lymph node harvest in colon can-
cer: influence of microsatellite instability and proxi-
mal tumor location. World J. Surg. 33:2695–703.
12. Belt EJ, et al. (2012) High lymph node yield is re-
lated to microsatellite instability in colon cancer.
Ann. Surg. Oncol. 19:1222–30.
13. Eveno C, et al. (2010) Association between a high
number of isolated lymph nodes in T1 to T4
N0M0 colorectal cancer and the microsatellite in-
stability phenotype. Arch. Surg. 145:12–7.
14. Nordgard O, et al. (2009) Quantitative RT-PCR
detection of tumor cells in sentinel lymph nodes
isolated from colon cancer patients with an ex
vivo approach. Ann. Surg. 249:602–7.
15. Bjugn R, Dirdal HU. (2001) Colorectal cancer: ex-
periences with the use of standardized forms for
reporting pathologic-anatomic data. Tidsskr Nor
Laegeforen 121:1697–701.
16. Umar A, et al. (2004) Revised Bethesda Guide-
lines for hereditary nonpolyposis colorectal can-
cer (Lynch syndrome) and microsatellite instabil-
ity. J. Natl. Cancer Inst. 96:261–8.
17. Gilje B, Heikkila R, Oltedal S, Tjensvoll K,
Nordgård O. (2008) High-fidelity DNA poly-
merase enhances the sensitivity of a peptide nu-
cleic acid clamp PCR assay for K-ras mutations.
J. Mol. Diagn. 10:325–31.
18. Oltedal S, et al. (2010) Detection of occult metas-
tases in sentinel lymph nodes from colon cancer
patients by K-ras mutation peptide nucleic acid
clamp PCR. Ann. Surg. 251:1087–91.
19. Ahlquist T, et al. (2008) RAS signaling in colorec-
tal carcinomas through alteration of RAS, RAF,
NF1, and/or RASSF1A. Neoplasia. 10:680–6.
20. Pallant J. (2010) Multiple regression. In: SPSS
Survival Manual. McGraw-Hill, London, pp.
148–67.
21. Lang TA, Secic M. (2006) Prediciting values from
one or more variables: reporting regression
analyses. In: How to Report Statistics in Medicine.
Annotated Guidelines for Authors, Editors, and Re-
viewers. Lang TA, Secic M, Eds. American College
of Physicians, Philadelphia, pp. 85–107.
22. Merok MA, et al. (2013) Microsatellite instability
has a positive prognostic impact on stage II colo-
rectal cancer after complete resection: results
from a large, consecutive Norwegian series. Ann.
Oncol. 24:1274–82.
23. Morikawa T, et al. (2012) Predictors of lymph
node count in colorectal cancer resections: data
from US nationwide prospective cohort studies.
Arch. Surg. 8:715–23.
24. Yamauchi M, et al. (2012) Assessment of colorec-
tal cancer molecular features along bowel sub-
sites challenges the conception of distinct di-
chotomy of proximal versus distal colorectum.
Gut. 61:847–54.
25. Sinicrope FA, Sargent DJ. (2012) Molecular path-
ways: microsatellite instability in colorectal can-
cer: prognostic, predictive and therapeutic impli-
cations. Clin. Cancer Res. 18:1506–12.
26. Ogino S, et al. (2012) Predictive and prognostic
roles of BRAF mutation in stage III colon cancer:
results from Intergroup Trial CALGB 89803. Clin.
Cancer Res. 18:890–900.
27. MacQuarrie E, et al. (2012) Microsatellite instabil-
ity status does not predict total lymph node or
negative lymph node retrieval in stage III colon
cancer. Hum. Pathol. 43:1258–64.
28. Yamauchi M, et al. (2012) Colorectal cancer: a tale
of two sides or a continuum? Gut. 61:794–7.
29. Alexander J, et al. (2001) Histopathological iden-
tification of colon cancer with microsatellite in-
stability. Am. J. Pathol. 158:527–35.
30. Phillips SM, et al. (2004) Tumour-infiltrating lym-
phocytes in colorectal cancer with microsatellite
instability are activated and cytotoxic. Br. J. Surg.
91:469–75.
31. Deschoolmeester V, Baay M, Lardon F, Pauwels
P, Peeters M. (2011) Immune cells in colorectal
cancer: prognostic relevance and role of MSI.
Cancer Microenviron. 4:377–92.
32. Nosho K, et al. (2010) Tumour-infiltrating T-cell
subsets, molecular changes in colorectal cancer,
and prognosis: cohort study and literature re-
view. J. Pathol. 222:350–66.
33. Parsons HM, et al. (2011) Association between
lymph node evaluation for colon cancer and
node positivity over the past 20 years. JAMA.
306:1089–97.
34. Porter GA, et al. (2012) Improving nodal harvest
in colorectal cancer: so what? Ann. Surg. Oncol.
19:1066–73.
35. Nash GM, et al. (2011) A predictive model for
lymph node yield in colon cancer resection speci-
mens. Ann. Surg. 253:318–22.
